

Chardan NexTech Acquisition 2 Corp.
17 State Street, 21st Floor
New York, NY 10004

VIA EDGAR

July 13, 2021

U.S. Securities & Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attn: Deanna Virginio

**Re: Chardan NexTech Acquisition 2 Corp.
Registration Statement on Form S-1
Filed March 8, 2021
Amendment No. 3 to Registration Statement on Form S-1
Filed June 4, 2021
File No. 333-254010**

Dear Ms. Virginio:

Chardan NexTech Acquisition 2 Corp., a Delaware corporation (the “**Company**,” “**we**,” “**our**” or “**us**”), hereby transmits the Company’s response to the comment letter received from the staff (the “**Staff**”) of the U.S. Securities and Exchange Commission (the “**Commission**”) dated June 17, 2021, regarding the Company’s Registration Statement on Form S-1 submitted to the Commission on March 8, 2021 (the “**Registration Statement**”) and Amendment No. 3 to Registration Statement on Form S-1 submitted to the Commission on June 4, 2021 (the “**Amended Registration Statement**”). For the Staff’s convenience, we have repeated below the Staff’s comment in bold, and have followed the comment with the Company’s response. Concurrently with the transmission of this letter, we are publicly filing the Company’s Amendment No. 2 to Registration Statement on Form S-1 with the Commission through EDGAR.

Amendment No. 3 to Registration Statement on Form S-1 filed June 4, 2021

Initial Business Combination

General, page 8

1. **Please clarify here and in the risk factors section that the public stockholders will not be entitled to vote or redeem their shares in connection with an extension from 18 months to up to 24 months to complete the business combination, as referenced on page 23. Please also describe the loans from insiders or their affiliates in the event of an extension under Certain Relationships and Related Party Transactions. Alternatively, please explain to us why such disclosure is not required.**
-

U.S. Securities & Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Attn: Deanna Virginio
Re: Chardan NexTech Acquisition 2 Corp.
July 13, 2021
Page 2 of 2

In response to the Staff's comment, we have revised in the Initial Business Combination and Risk Factors sections to clarify that the public stockholders will not be entitled to vote or redeem their shares in connection with such extensions. We have revised to describe the loans from insiders or their affiliates in the event of an extension under Certain Relationships and Related Party Transactions.

We thank the Staff for its review of the foregoing and the Amended Registration Statement. If you have further comments, please feel free to contact to our counsel, Ari Edelman, at aedelman@reedsmith.com or by telephone at (212) 521-4234.

Sincerely,

/s/ Jonas Grossman

Jonas Grossman
Chief Executive Officer
Chardan NexTech Acquisition 2 Co.

cc: Ari Edelman, Esq.
